Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00554450 · ClinicalTrials.gov registry record · Phase 1
Renal Impairment in Type 2 Diabetic Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00554450 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 40 participants.
The verdict
NCT00554450, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with normal renal function
Interventions
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00554450
The ClinicalTrials.gov registry entry for NCT00554450 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dapagliflozin is the first listed.
NCT00554450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00554450 about?
NCT00554450 is a clinical study titled "Renal Impairment in Type 2 Diabetic Subjects". The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with normal renal function
What is the current status of trial NCT00554450?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00554450?
The interventions under investigation include: Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00554450?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.